---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Definition and etiology"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Definition and etiology. Topics: Definition: autoantibody-mediated disorder of neuromuscular transmission, Generalized and ocular forms, Etiology: autoantibody subgroups, Etiology: thymus pathology and age at onset, and 1 further topic. 5 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description/definition-and-etiology"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Definition and etiology

<a id="heading-2.2.1.1"></a>

## 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

### Definition: autoantibody-mediated disorder of neuromuscular transmission

> “Myasthenia gravis (MG) is an autoimmune neurological disorder characterized by defective transmission at the neuromuscular junction.”
> “MG is considered a classic example of antibody-mediated autoimmune disease.”
> “These autoantibodies disrupt cholinergic transmission between nerve terminals and muscle fibers by causing downregulation, destruction, functional blocking of AChRs, or disrupting the clustering of AChRs in the postsynaptic membrane.”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

> “Myasthenia gravis (MG) is an autoimmune disease caused by antibodies against the acetylcholine receptor (AChR), muscle-specific kinase (MuSK) or other AChR-related proteins in the postsynaptic muscle membrane.”
> “Localized or general muscle weakness is the predominant symptom and is induced by the antibodies.”
> “Patients are grouped according to the presence of antibodies, symptoms, age at onset and thymus pathology.”

Source: [Gilhus et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31048702/)

<a id="topic-2.2.1.1-2"></a>

### Generalized and ocular forms

> “MG presents in two forms: ocular (oMG), affecting the levator palpebrae superioris, orbicularis oculi, and extraocular muscles, and generalized (gMG), involving bulbar, axial, limb, and respiratory muscles”

Source: [Barnett-Tapia et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13498700/)

> “Most patients have generalized weakness affecting the extraocular, bulbar, trunk, and extremity muscles.”
> “In 20% of MG patients, the muscle weakness remains confined to the extraocular muscles”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

> “It is the prototypic autoimmune disease most commonly caused by antibodies to the acetylcholine receptor (AChR) leading to characteristic fatigable weakness of the ocular, bulbar, respiratory, axial, and limb muscles.”

Source: [Hehir and Silvestri (2018)](https://pubmed.ncbi.nlm.nih.gov/29655448/)

<a id="topic-2.2.1.1-3"></a>

### Etiology: autoantibody subgroups

> “Antibodies against the AChR are found in approximately 80% of MG patients.”
> “AChR antibodies are predominantly of the IgG1 and IgG3 subclasses”
> “Antibodies against MuSK are found in approximately 7–10% of all MG patients and up to 40% of patients with generalized MG who are seronegative for AChR Abs.”
> “Lrp4 antibodies are present in 2–50% of double seronegative MG cases”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

> “In around 10% of patients with generalized MG, no antibodies are detected by standard testing.”
> “Many of these patients have low‐concentration or low‐affinity AChR antibodies when tested with more sensitive methods”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.1.1-4"></a>

### Etiology: thymus pathology and age at onset

> “Most MG patients have pathogenic autoantibodies against the extracellular part of acetylcholine receptors (AChR), commonly associated with an abnormal thymus.”
> “Thymoma is present in 10% of such patients, and thymic hyperplasia with ectopic germinal centers appears in most patients with symptom onset before age 50 years”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

> “Early-onset MG (EOMG) corresponds to patients presenting before age 50.”
> “Late-onset MG (LOMG) is defined by onset after the age of 50.”
> “MG is the most common paraneoplastic disorder associated with thymoma.”
> “Conversely, 10–20% of patients with MG have thymomas”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

<a id="topic-2.2.1.1-5"></a>

### Etiology: genetic susceptibility

> “There is frequent association of A1-B8-DR3 haplotype with early-onset MG”
> “A large genome-wide association study involving patients from North America and Italy identified different haplotypes across the HLA region, cytotoxic T-lymphocyte-associated protein 4 gene (CTLA4) and tumor necrosis factor receptor 4 superfamily, member 11a, (TNFRSF11A) and NFκB activator genes in early- and late-onset MG cases”

Source: [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
